NEW YORK (GenomeWeb) – Meridian Bioscience today reported its first quarter revenues fell 1 percent, due in part to continued weakness in its core diagnostics business.

For the three months ended Dec. 31, 2016, revenues fell to $46.8 million from $47.2 million a year ago, well below Wall Street analysts' average estimate of $51.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.